0.237 0.013 (5.66%) | 09-22 15:59 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.33 | 1-year : | 0.44 |
Resists | First : | 0.28 | Second : | 0.37 |
Pivot price | 0.18 | |||
Supports | First : | 0.14 | Second : | 0.11 |
MAs | MA(5) : | 0.18 | MA(20) : | 0.18 |
MA(100) : | 0.25 | MA(250) : | 0.51 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 39.2 | D(3) : | 32.7 |
RSI | RSI(14): 54.1 | |||
52-week | High : | 2.65 | Low : | 0.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HILS ] has closed below upper band by 23.4%. Bollinger Bands are 31.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.21 - 0.21 | 0.21 - 0.22 |
Low: | 0.17 - 0.17 | 0.17 - 0.17 |
Close: | 0.21 - 0.21 | 0.21 - 0.21 |
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
Fri, 22 Mar 2024
Hillstream BioPharma (NASDAQ:HILS) Stock Price Down 1.2% - Defense World
Fri, 22 Sep 2023
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change ... - Yahoo Finance
Tue, 02 May 2023
Hillstream BioPharma Announces Closing of Public Offering of Common Stock - Yahoo Finance
Thu, 27 Apr 2023
Hillstream BioPharma Announces Proposed Public Offering - GlobeNewswire
Thu, 27 Apr 2023
Hillstream BioPharma Announces Pricing of Public Offering - GlobeNewswire
Wed, 12 Apr 2023
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To ... - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 18 (M) |
Shares Float | 11 (M) |
Held by Insiders | 38.9 (%) |
Held by Institutions | 0.8 (%) |
Shares Short | 53 (K) |
Shares Short P.Month | 133 (K) |
EPS | -0.7 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.18 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -78 % |
Return on Equity (ttm) | -147.4 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -7 (M) |
Levered Free Cash Flow | -4 (M) |
PE Ratio | -0.3 |
PEG Ratio | 0 |
Price to Book value | 1.16 |
Price to Sales | 0 |
Price to Cash Flow | -0.5 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |